Roche and MedImmune will concoct lung cancer immunotherapy clinical trial test

Roche's ($RHHBY) Ventana Medical Systems and MedImmune said they will jointly develop an assay to help test a MedImmune immunotherapy for non-small cell lung cancer. Neither side is disclosing financial details. Specifically, they'll develop a PD-L1 (SP263) immunohistochemistry assay to enroll patients in clinical trials for MedImmune's MEDI4736, an anti-PD-L1 therapy. According to the companies, signals from PD-L1 help tumors avoid immune system detection. The idea is that MedImmune's treatment could combat this by targeting PD-L1, and Roche/Ventana will develop a test that screens for patients who may benefit most from the cancer immunotherapy. Release

Suggested Articles

InterVene secured $15 million to validate its catheter-based treatment for correcting failed one-way valves in the veins of the legs.

LabCorp, Philips and Mount Sinai are coming together to develop an AI-driven pathology center of excellence, aimed initially at cancer diagnosis.

The FDA followed through with plans to end its Alternative Summary Reporting program, making 20 years’ worth of device safety data publicly available.